Abstract:Bile acids (BAs) have attracted attention in the research of irritable bowel syndrome with predominant diarrhea (IBS-D) due to their ability to modulate bowel function and their tight connection with the gut microbiota. The composition of the fecal BA pool in IBS-D patients is reportedly different from that in healthy populations. We hypothesized that BAs may participate in the pathogenesis of IBS-D and the altered BA profile may be correlated with the gut microbiome.To investigate the role of BAs in the pathogenesis of IBS-D and the correlation between fecal BAs and gut microbiota.Fifty-five IBS-D patients diagnosed according to the Rome IV criteria and twenty-eight age-, sex-, and body mass index-matched healthy controls (HCs) were enrolled in this study at the gastroenterology department of China-Japan Friendship Hospital. First, clinical manifestations were assessed with standardized questionnaires, and visceral sensitivity was evaluated the rectal distension test using a high-resolution manometry system. Fecal primary BAs including cholic acid (CA) and chenodeoxycholic acid (CDCA), secondary BAs including deoxycholic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) as well as the corresponding tauro- and glyco-BAs were examined by ultraperformance liquid chromatography coupled to tandem mass spectrometry. The gut microbiota was analyzed using 16S rRNA gene sequencing. Correlations between fecal BAs with clinical features and gut microbiota were explored.Fecal CA (IBS-D: 3037.66 [282.82, 6917.47] nmol/g, HC: 20.19 [5.03, 1304.28] nmol/g; < 0.001) and CDCA (IBS-D: 1721.86 [352.80, 2613.83] nmol/g, HC: 57.16 [13.76, 1639.92] nmol/g; < 0.001) were significantly increased, while LCA (IBS-D: 1621.65 [58.99, 2396.49] nmol/g, HC: 2339.24 [1737.09, 2782.40]; = 0.002] and UDCA (IBS-D: 8.92 [2.33, 23.93] nmol/g, HC: 17.21 [8.76, 33.48] nmol/g; = 0.025) were significantly decreased in IBS-D patients compared to HCs. Defecation frequency was positively associated with CA ( = 0.294, = 0.030) and CDCA ( = 0.290, = 0.032) and negatively associated with DCA ( = -0.332, = 0.013) and LCA ( = -0.326, = 0.015) in IBS-D patients. In total, 23 of 55 IBS-D patients and 15 of 28 HCs participated in the visceral sensitivity test. The first sensation threshold was negatively correlated with CDCA ( = -0.459, = 0.028) in IBS-D patients. Furthermore, the relative abundance of the family was significantly decreased in IBS-D patients ( < 0.001), and 12 genera were significantly lower in IBS-D patients than in HCs ( < 0.05), with 6 belonging to . Eleven of these genera were negatively correlated with primary BAs and positively correlated with secondary BAs in all subjects.The altered metabolism of BAs in the gut of IBS-D patients was associated with diarrhea and visceral hypersensitivity and might be ascribed to dysbiosis, especially the reduction of genera in .

Altered gut microbiota–host bile acid metabolism in IBS-D patients with liver depression and spleen deficiency pattern

Gut Microbial Clues to Bipolar Disorder: State‐of‐the‐art Review of Current Findings and Future Directions

Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome

FMT and TCM to treat diarrhoeal irritable bowel syndrome with induced spleen deficiency syndrome- microbiomic and metabolomic insights

Altered Intestinal Microbiota with Increased Abundance of Prevotella is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome.

The Landscape of Gut Microbiota and Its Metabolites: A Key to Understanding the Pathophysiology of Pattern in Chinese Medicine

Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity

The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome

Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome

Enhancing Clinical Efficacy Through the Gut Microbiota: A New Field of Traditional Chinese Medicine

Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

Intestinal Crosstalk between Bile Acids and Microbiota in irritable bowel syndrome

Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

Cocultivation of Chinese prescription and intestine microbiota: SJZD alleviated the major symptoms of IBS-D subjects by tuning neurotransmitter metabolism

Bile acids as signaling molecules in inflammatory bowel disease: Implications for treatment strategies

An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome

Co-occurrence of gut microbiota dysbiosis and bile acid metabolism alteration is associated with psychological disorders in Crohn's disease

Sex-based Differences in Fecal Short-Chain Fatty Acid and Gut Microbiota in Irritable Bowel Syndrome Patients